ATLANTA, Jan. 10, 2013 (GLOBE NEWSWIRE) -- novoGI Inc. today announced that the American Journal of Surgery published the results of a major 1180-patient multinational, multicenter analysis of the company's compression anastomosis technology. Significant findings reported in "Compression Anastomosis Ring Device in Colorectal Anastomosis: A Review of 1,180 Patients" include low leak rates of 3.2% overall for end-to-end anastomosis and only 1.9% for low anterior resection (LAR) procedures with the company's novoGI™ ColonRing device.1
In addition to the low leak rates reported, median length of hospital stay was 6 days and median time for natural excretion of the ColonRing was 8 days. Summarizing the results, the authors stated, "Our study involved the largest number of end-to-end colorectal anastomoses using the ColonRing device to date. The rate of anastomotic leak is relatively low with the use of the ColonRing for both open and laparoscopic colorectal anastomoses. The device failure rate is very low, and problems with ring expulsion are not significant. End-to-end colorectal anastomosis with the ColonRing is feasible and safe and may lead to decreased anastomotic complications in low anastomoses resulting in lower morbidity and lower mortality."
"The important results reported in this latest publication of the American Journal of Surgery are consistent with peer-review clinical evidence demonstrating better outcomes for anastomosis with the novoGI™ ColonRing," commented novoGI President and Chief Executive Officer, Gavriel D. Meron. "These results support the goal of displacing the use of staples in colorectal anastomoses and creating a new standard of care."
1. Masoomi H, Luo R, Mills S, Carmichael JC, Senagore AJ, Stamos MJ. Compression anastomosis ring device in colorectal anastomosis: a review of 1,180 patients. Am J Surg. 2013. [Published online ahead of print] doi:10.1016/j.amjsurg.2012.03.013. Available at: http://www.americanjournalofsurgery.com/article/S0002-9610(12)00580-6/abstract
About novoGI
novoGI is focused on providing an expanding range of solutions for GI disease management through a globally branded, high quality, market driven company. The U.S. headquarters are in Atlanta, Georgia; research, development and manufacturing facilities in Netanya, Israel; and its European headquarters are near Paris, France. The company's website is www.novoGI.com.
NOVOGI, the NOVOGI logo, the GI logo, and DEFINING THE FUTURE are trademarks and/or registered trademarks of novoGI Inc.
For further information contact: marcom@novoGI.com